A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.Elizabeth Ruth Plummer, Udai Banerji, T.R. Jeffry Evans et al.|Journal of Clinical Oncology|2019Cited by 31